Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization

Nature Medicine

Volumn 4, Issue 8, 1998, Pages 923-928

  Bajou, K ^a   Noel A ^a   Gerard, R D ^b   Masson, V ^a   Brunner, N ^c   Holst Hansen, C ^c   Skobe, M ^d   Fusenig, N E ^d   Carmeliet, P ^b   Collen, D ^b   Foidart, J M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c FINSEN LABORATORY   (Denmark)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; UROKINASE;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER INVASION; CANCER SURVIVAL; KERATINOCYTE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADENOVIRIDAE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; GENETIC VECTORS; GENOTYPE; HUMANS; KERATINOCYTES; MALE; MESODERM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; SKIN NEOPLASMS; TRANSFECTION;

ANIMALIA;

EID: 0031902286     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0898-923     Document Type: Article

References (42)

1. Blasi, F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15, 105-111 (1993).
2. Mignatti, P. & Rifkin, D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161-195 (1993).
3. Murphy, G., Atkinson, S., Ward, R., Gavrilovic, J. & Reynolds, J.J. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann. NY Acad. Sci. 667, 1-12 (1992).
4. Andreasen, P.A., Kjoller, L., Christensen, L. & Duffy, M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72, 1-22 (1997).
5. Ossowski, L., Russo-Payne, H. & Wilson E.L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 51, 274-281 (1991).
6. Yu, H.R. & Schultz R.M. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. 50, 7623-7633 (1990).
7. Heiss, M.M. et al. Tumor associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol. 13, 2084-2093 (1995).
8. Pyke, C., Kristensen, P., Ralfkiaer, E., Eriksen, J. & Dano, K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 51, 4067-4071 (1991).
9. Sier, C.F.M. et al. Inactive urokinase and increased levels of its inhibitor type I in colorectal cancer liver metastasis. Gastroenterology 107, 1449-1456 (1994).
10. Liu, G., Shuman M.A. & Cohen R.L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer 60, 501-506 (1995).
11. Grondhal-Hansen, J. et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53, 2513-2521 (1993).
12. Pedersen, H. et al. Prognostic impact of urokinase, urokinase receptor, and type I plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54, 4671-4675 (1994).
13. Kuhn, W. et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol. 55, 401-409 (1994).
14. Kruithof, E.K., Gudinchet, A., & Bachmann, F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb. Haemost. 59, 7-12 (1988).
15. Deng, G., Curriden, S.A., Wang, S., Rosenberg, S. & Loskutoff, D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1-9 (1996).
16. Chapman, H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell. Biol. 9, 714-724(1997).
17. Fusenig, N.E., Amer, S.M., Boukamp, P. & Worst, K.M. Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo. Bull. Cancer 65, 271-280 (1978).
18. Carmeliet, P. et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J. Clin. Invest. 92, 2746-2755 (1993).
19. Carmeliet, P. et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J. Clin. Invest. 92, 2756-2760 (1993).
20. DeClerck, P.J., Verstreken, M. & Coolen, D. Immunoassay of murine t-PA, uPA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thomb Haemost. 74, 1 305-1 309 (1995).
21. Lijnen, R.H., Moons, L., Beelen, V., Carmeliet, P. & Collen, D. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice. Thromb. Haemost. 74, 1126-1131(1995).
22. Nakamura, M. et al. Possible rote of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissue. Thromb. Res. 65, 709-719 (1992).
23. Nakarda, H. et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 54, 2900-2907 (1994).
24. Foekens, J.A. et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J. Clin. Oncol. 12, 1648-1658 (1994).
25. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S. & Fusenig, N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. 3, 1222-1227 (1997).
26. Bacharach, E., Itin, A., & Keshet, E. In vivo patterns of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc. Natl. Acad. Sci. USA 89, 1 0686-1 0690 (1992).
27. Bianchi, E. et al. Immunohistochemical localization of plasminogen activator inhibitor-1 in breast cancer. Int. J. Cancer 60, 597-603 (1995).
28. Schnaper, H.W. et al. Plasminogen activators augment endothelial organization in vitro by two distinct pathways. J. Cell. Physiol. 165, 107-118 (1995).
29. Montesano, R. et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62, 435-445 (1990).
30. Pepper, M.S., Sappino, A.P., Montesano, R., Orci, L. & Vassalli, J.-D. Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J. Cell. Physiol. 153, 129-139 (1992).
31. Kanse, S.M., Kost, C., Wilhelm, O.G., Andreasen, P.A. & Preissner, K.T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224, 344-353 (1996).
32. Stefansson, S. & Lawrence, D.A. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature 383, 441-443 (1996).
33. Waltz, D.A., Natkin, L.R., Fujita, R.M., Wei, Y. & Chapman H. A. Plasmin and plasminogen activator type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100, 58-67 (1997).
34. Boukamp, P., Stanbridge, E.J., Foo, D.Y., Cerutti, P.A. & Fusenig, N.E. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res. 50, 2840-2847 (1990).
35. Fusenig, N.E. in The Keratinocyte Handbook. (eds. Leigh, I., Lane, B., Watt, F.) 71-49 (Cambridge Univ. Press, Cambridge, 1994).
36. Carmeliet, P., Moons, L., Ploplis, V., Plow, E. & Collen, D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99, 200-208 (1997).
37. Kristensen, P., Pyke, C., Lund, L.R., Andreasen, P.A. & Dano, K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry 93, 559-566 (1990).
38. Prendergast, G.C., Diamond, L.E., Dahl, D. & Cole, M.D. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol. Cell. Biol. 10, 1265-1269 (1990).
39. Kristensen, P., Eriksen, J., Blasi, F. & Dano, K. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localisation in the gastrointestinal tract. J. Cell Biol. 115, 1763-1771 (1991).
40. de Vries, T.J., Kitson, J.L., Silvers, W.K. & Mintz, B. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice. Cancer Res. 55, 4681-4687 (1995).
41. Sappino, A.P. et al. Differential protease expression by cutaneous squamous and basal cell carcinomas. J. Clin. Invest. 88, 1073-1079 (1991).
42. Carmeliet, P. et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 96, 3180-3191 (1997).